Although β-lactamases have always been considered enzymes involved in resistance to β-lactam antibiotics, they also have to be considered as playing a role in reshaping bacterial physiology. By studying a series of class C β-lactamases, we uncovered an unexpected dual role. Besides conferring resistance to β-lactams, they also impact bacterial growth, motility, and pathogenicity through modulation of flagellar biosynthesis. Strikingly, while CMY-42- and CMY-145-producing recombinant Escherichia coli strains showed enhanced in vitro fitness growth by reducing energy-costly flagellar production, production of CMY-2 (the most commonly identified acquired AmpC β-lactamase identified in Enterobacterales) restored flagella and increased virulence in vivo. This work reframes β-lactamases as metabolic regulators influencing ecological success, offering new insight into how resistance determinants promote the spread and clinical impact of Enterobacterales.
Raro et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: